Contrasting Neuronetics (NASDAQ:STIM) & Mobia Medical (NASDAQ:MOBI)

Mobia Medical (NASDAQ:MOBI) and Neuronetics (NASDAQ:STIM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Mobia Medical and Neuronetics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mobia Medical	1	1	5	0	2.57
Neuronetics	1	0	4	0	2.60

Mobia Medical presently has a consensus target price of $20.75, suggesting a potential upside of 84.12%. Neuronetics has a consensus target price of $4.67, suggesting a potential upside of 96.08%. Given Neuronetics’ stronger consensus rating and higher possible upside, analysts plainly believe Neuronetics is more favorable than Mobia Medical.

Institutional & Insider Ownership

53.6% of Neuronetics shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Mobia Medical and Neuronetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mobia Medical	N/A	N/A	N/A
Neuronetics	-19.62%	-125.11%	-22.15%

Earnings and Valuation

This table compares Mobia Medical and Neuronetics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mobia Medical	$32.04 million	11.71	-$46.50 million	($20.18)	-0.56
Neuronetics	$149.16 million	1.22	-$39.00 million	($0.44)	-5.41

Neuronetics has higher revenue and earnings than Mobia Medical. Neuronetics is trading at a lower price-to-earnings ratio than Mobia Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Neuronetics beats Mobia Medical on 7 of the 12 factors compared between the two stocks.

About Mobia Medical

Mobia Medical Inc. is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc. is based in AUSTIN, Texas.

About Neuronetics

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.